Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Cellectis S.A.. (1/2/18). "Press Release: Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00PM PT". New York, NY.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
  Group Cellectis (Group)
  Organisation 2 J.P. Morgan Investment Management Inc.
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 36th Annual Healthcare Conference 2018 San Francisco
  Product 2 TALEN (Transcription Activator-Like Effector Nuclease)
Index term Index term Cellectis–JPMorgan Chase: investor conference, 201801 supply service Cellectis presents at JP Morgan Healthcare Conference 2018
Persons Person Choulika, André (Cellectis 200701 CEO + co-founder)
  Person 2 Harnest, Simon (Cellectis 201505 VP Finance + Investor Relations before Trout Group)
     


Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that Dr. André Choulika, Chairman and Chief Executive Officer of Cellectis, will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 p.m. Pacific Time in the Elizabethan A/B room. A Q&A session will follow at 1:30 p.m. PT in the Sussex room. The conference will be held from January 8 to 11, 2018 at the Westin St. Francis Hotel in San Francisco, CA.

To access the live webcast of Cellectis presentation and subsequent breakout session, please visit http://www.cellectis.com/en/agenda/. A replay of the webcast will be available on Cellectis website for 90 days.


About Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.


For further information, please contact:

Media contacts:

Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, ckasunich@kcsa.com

IR contact:
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com


Disclaimer

This press release contains “forward-looking” statements that are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Further information on the risks factors that may affect company business and financial performance, is included in filings Cellectis makes with the Security Exchange Commission from time to time and its financial reports. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forwardlooking statements, even if new information becomes available in the future. ###

   
Record changed: 2018-02-23

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October iito 600x60px

More documents for Cellectis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top